Skip to content

Septorhinoplasty Post-operative Pain Control With SPG Nerve Block

Post-operative Pain Control With Sphenopalantine Ganglion Nerve Block in Septorhinoplasty Patients

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05667324
Enrollment
50
Registered
2022-12-28
Start date
2023-04-12
Completion date
2025-02-28
Last updated
2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Deviated Nasal Septum

Keywords

Post-op pain, septorhinoplasty, deviated septum

Brief summary

Maxillary nerve blocks have been shown to significantly reduce post-operative pain and analgesic intake during the 24-hour period following sinus surgery. This randomized, double-blinded, placebo-controlled study will investigate blocks of the sphenopalatine ganglion using a suprazygomatic approach during septorhinoplasty surgery. It is the investigator's hypothesis that this technique will result in decreased post-operative pain and opioid use, and the morbidity associated with it.

Interventions

DRUGRopivacaine

A single injection into the pterygopalatine fossa bilaterally of 0.5% ropivacaine at a dose of 20 mg (each side)

DRUGDexamethasone

Plus 4 mg dexamethasone

DRUGPlacebo

A single injection into the pterygopalatine fossa bilaterally of a balanced crystalloid intravenous solution (4 ml of normal saline)

Sponsors

University of Florida
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Patient presenting for open or endoscopic septorhinoplasty * Age 18-80 * Normal oral food and water intake before surgery * ASA physical classification 1-3

Exclusion criteria

* Refusal to consent * Patients without a cellular phone or who are unable to accept text messages * Allergy to opioid narcotics * ASA physical classification of 4 or higher * Patient requires other surgery in addition to septorhinoplasty * Age \> 80 or \<18 * Any underlying chronic pain condition or ongoing opioid use over the preceding 3 months * Presence of any other factor which, at the discretion of any member of the study team, makes the patient a poor candidate for block placement. * Presence of any other factor which, at the discretion of any member of the study team, makes the patient a poor candidate for research participation. * Pregnant women

Design outcomes

Primary

MeasureTime frameDescription
Post Operative Pain Scores5 days +/- 2 daysTo assess if bilateral sphenopalatine nerve blocks can decrease post operative pain scores on a scale from 0-10, with a 0 meaning no pain and 10 meaning extreme pain. Pain scores were assessed on post operative days 1, 3 and 5.

Secondary

MeasureTime frameDescription
Post Anesthesia Care Unit Duration60-180 minutesTo assess if bilateral sphenopalatine nerve blocks results in decreased post-anesthesia care unit observation time (assessed in minutes). Patients are transferred to the post-anesthesia care units immediately following completion of surgery.
Text Message Survey Collection5 days post-operatively +/- 1 dayTo assess the efficiency of SMS based survey for post-operative data collection

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORJeffrey D Johnson, MD

University of Florida

Participant flow

Pre-assignment details

Once participants met inclusion and exclusion criteria, and consented to participate in the study, they were assigned to 1 of 2 study arms, experimental arm or placebo arm.

Baseline characteristics

Characteristic
Age, Customized
Age
40.1 age (years)
STANDARD_DEVIATION 15.9
Race and Ethnicity Not Collected0 Participants
Sex: Female, Male
Female
10 Participants
Sex: Female, Male
Male
19 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 220 / 24
other
Total, other adverse events
0 / 220 / 24
serious
Total, serious adverse events
0 / 220 / 24

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 28, 2026